Confirmation of p-tau Ser356’s association with Alzheimer’s disease pathology and lowering in response to WZ4003 treatment in brain slice cultures. Reply to: “Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer’s pathology”

This dataset relates to correspondence by Taylor et al. Here we repeat some key experiments from Taylor et al 2024 using the more more specific antibody ab92682. We find that the core findings from our original Taylor et al 2024 paper are robust and reproducible. Using the more specific ab92682 antibody we find that: 1. P-tau Ser356 increases in a Braak stage-dependent manner in human post-mortem temporal cortex (western blot); 2. P-tau Ser356 co-localises with methoxy positive tangles in AD post-mortem brain (both in paraffin sections and using array tomography); 3. P-tauSer356 co-localises with pre-synaptic terminals and astrocytic processes in AD post-mortem brain (array tomography); 4. P-tau Ser356 levels are lowered in response to treatment with the NUAK1/2 inhibitor WZ4003 in live brain slice cultures (mouse organotypic brain slice cultures).